Avalyn IPO Closes, Underwriters Fully Exercise Overallotment for $345M Gross Proceeds
AVLN is trading near its 52-week low of $26 (14% above the low) on light trading volume (0.2× avg).
Summary
Avalyn Pharma announced the closing of its initial public offering, including the full exercise of the underwriters' overallotment option to purchase an additional 2,500,000 shares. This brings the total shares sold to 19,166,667 at $18.00 per share, resulting in aggregate gross proceeds of $345 million. This news follows the company's IPO pricing announcement and an SEC filing confirming the completion of the initial offering. The full exercise of the overallotment is a significant positive, indicating strong market demand for Avalyn's stock and providing the clinical-stage biopharmaceutical company with substantial additional capital to advance its inhaled therapies for rare respiratory diseases. Investors will now monitor the company's use of these funds to progress its pipeline.
At the time of this announcement, AVLN was trading at $29.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $26.00 to $30.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.